{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:26:56Z","timestamp":1786948016713,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02273-6","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T03:06:27Z","timestamp":1785380787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic factor analysis of CD19 CAR-T therapy followed by hematopoietic stem cell transplantation in relapsed\/refractory B-ALL"],"prefix":"10.1007","volume":"26","author":[{"given":"Xin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jile","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"issue":"16","key":"2273_CR1","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2015;373(16):1541\u201352.","journal-title":"N Engl J Med"},{"issue":"6","key":"2273_CR2","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood cancer J. 2017;7(6):e577.","journal-title":"Blood cancer J"},{"issue":"10230","key":"2273_CR3","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","volume":"395","author":"F Malard","year":"2020","unstructured":"Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet (London England). 2020;395(10230):1146\u201362.","journal-title":"Lancet (London England)"},{"key":"2273_CR4","doi-asserted-by":"crossref","unstructured":"Soumyadeep D, Mark RLJBA. Immunotherapy in the up-front treatment of adult B-cell precursor acute lymphoblastic leukemia: when, how, who? 2026;10(4).","DOI":"10.1182\/bloodadvances.2025015936"},{"issue":"15","key":"2273_CR5","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1200\/JCO.20.02262","volume":"39","author":"NN Shah","year":"2021","unstructured":"Shah NN, Lee DW, Yates B, Yuan CM, Shalabi H, Martin S, et al. Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. J Clin oncology: official J Am Soc Clin Oncol. 2021;39(15):1650\u20139.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"12","key":"2273_CR6","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","volume":"106","author":"JM Rowe","year":"2005","unstructured":"Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993. Blood. 2005;106(12):3760\u20137.","journal-title":"Blood"},{"key":"2273_CR7","doi-asserted-by":"publisher","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","volume":"14","author":"A Mitra","year":"2023","unstructured":"Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023;14:1188049.","journal-title":"Front Immunol"},{"issue":"12","key":"2273_CR8","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1007\/s00262-021-02941-4","volume":"70","author":"W Lu","year":"2021","unstructured":"Lu W, Wei Y, Cao Y, Xiao X, Li Q, Lyu H, et al. CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease. Cancer Immunol immunotherapy: CII. 2021;70(12):3501\u201311.","journal-title":"Cancer Immunol immunotherapy: CII"},{"issue":"5","key":"2273_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, Wang X, S\u00e9n\u00e9chal B, Curran KJ, et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):449\u201359.","journal-title":"N Engl J Med"},{"key":"2273_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","volume":"14","author":"M Ruella","year":"2016","unstructured":"Ruella M, Maus MV. Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies. Comput Struct Biotechnol J. 2016;14:357\u201362.","journal-title":"Comput Struct Biotechnol J"},{"issue":"10","key":"2273_CR11","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMx160005","volume":"374","author":"Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia","year":"2016","unstructured":"Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia. Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med. 2016;374(10):998.","journal-title":"N Engl J Med"},{"issue":"26","key":"2273_CR12","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","volume":"360","author":"CH Pui","year":"2009","unstructured":"Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360(26):2730\u201341.","journal-title":"N Engl J Med"},{"issue":"5","key":"2273_CR13","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","volume":"29","author":"R Bassan","year":"2011","unstructured":"Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin oncology: official J Am Soc Clin Oncol. 2011;29(5):532\u201343.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"2273_CR14","doi-asserted-by":"crossref","unstructured":"Florian C, Nathalie D, Nicolas BJLL. Allogeneic hematopoietic stem cell transplantation in adult with acute lymphoblastic leukemia: evolving indications and modalities in shifting landscape. 2025;67(2).","DOI":"10.1080\/10428194.2025.2584685"},{"key":"2273_CR15","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jare.2025.02.006","volume":"78","author":"T Yang","year":"2025","unstructured":"Yang T, Dong Y, Shi J, Zhang M, Kong D, Feng J, et al. Sequential allogeneic HSCT after CAR-T therapy for relapsed\/refractory acute lymphoblastic leukemia patients: A long-term follow-up result. J Adv Res. 2025;78:461\u20139.","journal-title":"J Adv Res"},{"issue":"15","key":"2273_CR16","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","volume":"133","author":"KA Hay","year":"2019","unstructured":"Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019;133(15):1652\u201363.","journal-title":"Blood"},{"issue":"1","key":"2273_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-020-00873-7","volume":"13","author":"H Zhao","year":"2020","unstructured":"Zhao H, Wei J, Wei G, Luo Y, Shi J, Cui Q, et al. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed\/refractory acute lymphoblastic leukemia: a multi-center retrospective study. J Hematol Oncol. 2020;13(1):42.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"2273_CR18","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","volume":"4","author":"X Zhang","year":"2020","unstructured":"Zhang X, Lu XA, Yang J, Zhang G, Li J, Song L, et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 2020;4(10):2325\u201338.","journal-title":"Blood Adv"},{"issue":"10","key":"2273_CR19","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/ajh.25582","volume":"94","author":"H Jiang","year":"2019","unstructured":"Jiang H, Li C, Yin P, Guo T, Liu L, Xia L, et al. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial. Am J Hematol. 2019;94(10):1113\u201322.","journal-title":"Am J Hematol"},{"issue":"13","key":"2273_CR20","doi-asserted-by":"publisher","first-page":"e33937","DOI":"10.1016\/j.heliyon.2024.e33937","volume":"10","author":"J Liu","year":"2024","unstructured":"Liu J, Xu M, Zhang X, Zhang Z, Zhong T, Yu H, et al. CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory\/relapsed B-cell acute lymphoblastic leukemia. Heliyon. 2024;10(13):e33937.","journal-title":"Heliyon"},{"issue":"4","key":"2273_CR21","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00277-021-04451-w","volume":"100","author":"L Hu","year":"2021","unstructured":"Hu L, Charwudzi A, Li Q, Zhu W, Tao Q, Xiong S, et al. Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R\/R B-ALL patients: a systematic review and meta-analysis. Ann Hematol. 2021;100(4):1003\u201312.","journal-title":"Ann Hematol"},{"key":"2273_CR22","unstructured":"Ning W, Jun K, Meng L, Xiao-Dong M, Yu-Qian S, Yi-Fei C et al. Bridging With Chimeric Antigen Receptor T-Cell Therapy or Chemotherapy to Allo-HSCT in B-ALL: A Comparison of Treatment Complications and Survival. 2026(0)."},{"issue":"2","key":"2273_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85\u201396.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2273_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"ML Schubert","year":"2021","unstructured":"Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, M\u00fcller-Tidow C, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Annals oncology: official J Eur Soc Med Oncol. 2021;32(1):34\u201348.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"key":"2273_CR25","doi-asserted-by":"crossref","unstructured":"Zhihui L, Tao Z, Qian F, Xianxuan W, Jing L, Yong T et al. Case Report: CAR-T cell therapy bridging to allogeneic hematopoietic stem cell transplantation triggers Purtscher-like retinopathy: clinical features and complement-mediated microvascular injury mechanisms. 2026;17(0).","DOI":"10.3389\/fimmu.2026.1670399"},{"key":"2273_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.cyto.2015.11.022","volume":"78","author":"GG Gan","year":"2016","unstructured":"Gan GG, Leong YC, Bee PC, Chin EF, Abdul Halim H, Nadarajan VS, et al. Influence of genetic polymorphisms of cytokine genes in the outcome of HLA-matched allogeneic stem cell transplantation in a South East Asian population. Cytokine. 2016;78:55\u201361.","journal-title":"Cytokine"},{"issue":"4","key":"2273_CR27","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/01.TP.0000111769.45088.A2","volume":"77","author":"C Mullighan","year":"2004","unstructured":"Mullighan C, Heatley S, Doherty K, Szabo F, Grigg A, Hughes T, et al. Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation. Transplantation. 2004;77(4):587\u201396.","journal-title":"Transplantation"},{"issue":"1","key":"2273_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","volume":"127","author":"JJ Cornelissen","year":"2016","unstructured":"Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127(1):62\u201370.","journal-title":"Blood"},{"issue":"12","key":"2273_CR29","doi-asserted-by":"publisher","first-page":"E322","DOI":"10.1002\/ajh.25630","volume":"94","author":"S Tu","year":"2019","unstructured":"Tu S, Huang R, Guo Z, Deng L, Song C, Zhou X, et al. Shortening the ex vivo culture of CD19-specific CAR T-cells retains potent efficacy against acute lymphoblastic leukemia without CAR T-cell-related encephalopathy syndrome or severe cytokine release syndrome. Am J Hematol. 2019;94(12):E322\u20135.","journal-title":"Am J Hematol"},{"key":"2273_CR30","doi-asserted-by":"crossref","unstructured":"XiaoYan C, LingLing W, CaiYun K, JiaYi W, WenGe H, Hua J et al. Pediatric acute lymphoblastic leukemia relapse and prognosis: key predictors and therapeutic implications. 2026;13(0).","DOI":"10.3389\/fped.2025.1710578"},{"issue":"4","key":"2273_CR31","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transpl. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2273_CR32","doi-asserted-by":"crossref","unstructured":"Wu L, Chen J, Cai R, Wang X, Liu Y, Zheng Q et al. Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia. Cancers (Basel). 2023;15(10).","DOI":"10.3390\/cancers15102767"},{"issue":"3","key":"2273_CR33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1586\/ehm.10.21","volume":"3","author":"B Gyurkocza","year":"2010","unstructured":"Gyurkocza B, Rezvani A, Storb RF. Allogeneic hematopoietic cell transplantation: the state of the art. Expert Rev Hematol. 2010;3(3):285\u201399.","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"2273_CR34","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15(12):1628\u201333.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"2273_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transpl. 2016;22(1):4\u201310.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"2273_CR36","first-page":"713","volume":"45","author":"[Chinese expert consensus on the diagnosis","year":"2024","unstructured":"[Chinese expert consensus on the diagnosis. and treatment of chronic graft-versus-host disease (2024)]. Zhonghua Xue Ye Xue Za Zhi. 2024;45(8):713\u201326.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"4","key":"2273_CR37","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3324\/haematol.2016.150250","volume":"102","author":"Y Inamoto","year":"2017","unstructured":"Inamoto Y, Lee SJ. Late effects of blood and marrow transplantation. Haematologica. 2017;102(4):614\u201325.","journal-title":"Haematologica"},{"key":"2273_CR38","doi-asserted-by":"publisher","first-page":"1048296","DOI":"10.3389\/fonc.2022.1048296","volume":"12","author":"Z Li","year":"2022","unstructured":"Li Z, Yang K, Song Y, Zhao Y, Wu F, Wen X, et al. CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory\/relapsed acute B lymphocytic leukemia: Long-term follow-up results. Front Oncol. 2022;12:1048296.","journal-title":"Front Oncol"},{"issue":"3","key":"2273_CR39","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4143\/crt.2023.1205","volume":"56","author":"Y Wang","year":"2024","unstructured":"Wang Y, Xue YJ, Zuo YX, Jia YP, Lu AD, Zeng HM, et al. CD19-Specific CAR-T Cell Treatment of 115 Children and Young Adults with Acute B Lymphoblastic Leukemia: Long-term Follow-up. Cancer Res Treat. 2024;56(3):945\u201355.","journal-title":"Cancer Res Treat"},{"key":"2273_CR40","doi-asserted-by":"crossref","unstructured":"Linhui H, Alice C, Qian L, Weiwei Z, Qianshan T, Shudao X et al. Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R\/R B-ALL patients: a systematic review and meta-analysis. 2021;100(4).","DOI":"10.1007\/s00277-021-04451-w"},{"key":"2273_CR41","doi-asserted-by":"crossref","unstructured":"Tingting Y, Yetian D, Jimin S, Mingming Z, Delin K, Jingjing F et al. Sequential allogeneic HSCT after CAR-T therapy for relapsed\/refractory acute lymphoblastic leukemia patients: A long-term follow-up result. 2025;78(0).","DOI":"10.1016\/j.jare.2025.02.006"},{"issue":"1\u20133","key":"2273_CR42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/17474086.2023.2298732","volume":"17","author":"Y Zhai","year":"2024","unstructured":"Zhai Y, Hong J, Wang J, Jiang Y, Wu W, Lv Y, et al. Comparison of blinatumomab and CAR T-cell therapy in relapsed\/refractory acute lymphoblastic leukemia: a systematic review and meta-analysis. Expert Rev Hematol. 2024;17(1\u20133):67\u201376.","journal-title":"Expert Rev Hematol"},{"key":"2273_CR43","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1182\/asheducation-2015.1.225","volume":"2015","author":"RS Negrin","year":"2015","unstructured":"Negrin RS. Graft-versus-host disease versus graft-versus-leukemia. Hematol Am Soc Hematol Educ Program. 2015;2015:225\u201330.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2273_CR44","doi-asserted-by":"crossref","unstructured":"Allison P, Xue-Zhong Y, Yongxia WJCOI. Cell death pathways in graft-versus-host disease. 2026;99(0).","DOI":"10.1016\/j.coi.2026.102740"},{"key":"2273_CR45","unstructured":"Daniela W, Misbah T, Mette H, Hendrik P, Florent MJBMT. Microbiome, GvHD, and immune reconstitution in allogeneic hematopoietic cell transplantation. 2026(0)."},{"key":"2273_CR46","doi-asserted-by":"crossref","unstructured":"Benjamin LS, Kylie D, Hanna LS, Barite G, Ronnie M, Carrie LK et al. Bidirectional Interactions: Microbiome and Immune System Function in Cutaneous Graft-Versus. -Host Disease. 2026;96(2).","DOI":"10.1097\/SAP.0000000000004450"},{"key":"2273_CR47","doi-asserted-by":"crossref","unstructured":"Adonai Blessington M, Albert CYJGM. The gut microbiome in graft-versus-host disease: mechanisms of immune modulation and therapeutic approaches. 2026;18(1).","DOI":"10.1080\/19490976.2026.2631224"},{"issue":"1","key":"2273_CR48","first-page":"1","volume":"37","author":"E Alada\u011f","year":"2020","unstructured":"Alada\u011f E, Kelkitli E, G\u00f6ker H. Acute Graft-Versus-Host Disease: A Brief Review. Turkish J haematology: official J Turkish Soc Haematol. 2020;37(1):1\u20134.","journal-title":"Turkish J haematology: official J Turkish Soc Haematol"},{"issue":"1","key":"2273_CR49","doi-asserted-by":"publisher","first-page":"2178805","DOI":"10.1080\/19490976.2023.2178805","volume":"15","author":"YF van Lier","year":"2023","unstructured":"van Lier YF, Vos J, Blom B, Hazenberg MD. Allogeneic hematopoietic cell transplantation, the microbiome, and graft-versus-host disease. Gut Microbes. 2023;15(1):2178805.","journal-title":"Gut Microbes"},{"key":"2273_CR50","doi-asserted-by":"publisher","first-page":"1525244","DOI":"10.3389\/fimmu.2024.1525244","volume":"15","author":"Z Xu","year":"2024","unstructured":"Xu Z, Wang H. Targeting the chemokines in acute graft-versus-host disease. Front Immunol. 2024;15:1525244.","journal-title":"Front Immunol"},{"issue":"7","key":"2273_CR51","doi-asserted-by":"publisher","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","volume":"3","author":"DA Berry","year":"2017","unstructured":"Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, et al. Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis. JAMA Oncol. 2017;3(7):e170580.","journal-title":"JAMA Oncol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02273-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02273-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02273-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:15:44Z","timestamp":1786947344000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02273-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2273"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02273-6","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Xin Wang, Linlin Liu, Yuanyuan Zhai, Jianmei Xu, Jile Liu, Hairong Lv and Mingfeng Zhao declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The diagnosis of all patients was conducted in accordance with the diagnostic criteria established by the WHO. This study has obtained approval from Medical Ethics Committee of Tianjin First Central Hospital. The patients participating in this study have all completed informed consent forms in accordance with the principles outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"300"}}